Recent developments: Must reads in IBD
- COVID-19
- 07/20
- 06/20
- 05/20
- 03/20
- 02/20
- 06-04/21
- 03-02/21
Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?
Monteleone G, Ardizzone S
J Crohns Colitis, 2020 Mar 26,pii: jjaa061. doi: 10.1093/ecco-jcc/jjaa061
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period
Iacucci M, Cannatelli R, Labarile N, Mao R, Panaccione R, Danese S, Kochhar GS, Ghosh S, Shen B
Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China
An P, Ji M, Ren H, Su J, Ding NS, Kang J, Yin A, Zhou Q, Shen L, Zhao L, Jiang X, Xiao Y, Tan W, Lv X, Li J, Liu S, Zhou J, Chen H, Xu Y, Liu J, Chen M, Cao J, Zhou Z, Shen L, Tan S, Yu H, Dong W, Ding Y
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok RC, Powell N, Probert CS, Raine T, Sebastian S, Selinger C, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW
Gut, 2020 Apr 17,pii: gutjnl-2020-321244. doi: 10.1136/gutjnl-2020-321244
Covid-19 and immunomodulation in IBD
Neurath MF
Gut, 2020 Apr 17,pii: gutjnl-2020-321269. doi: 10.1136/gutjnl-2020-321269
Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds
Bezzio C, Manes G, Bini F, Pellegrini L, Saibeni S
Gut, 2020 Jun 17,pii: gutjnl-2020-321760. doi: 10.1136/gutjnl-2020-321760
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F, Cooney R, Dart RJ, Galloway J, Gaya DR, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees CW, Limdi JK, Lindsay JO, Patel K, Powell N, Murray CD, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan MA, Irving PM
Gut, 2020 Jun 8,pii: gutjnl-2020-321927. doi: 10.1136/gutjnl-2020-321927
Impact of Anti-TNF and Thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: A Nationwide VA cohort study
Khan N, Patel D, Xie D, Lewis J, Trivedi C, Yang YX
Gastroenterology, 2020 May 29,pii: S0016-5085(20)34737-5. doi: 10.1053/j.gastro.2020.05.065
Innovation in IBD Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey by the International Organization for the Study of Inflammatory Bowel Disease
Lees CW, Regueiro M, Mahadevan U, International Organization for the Study of Inflammatory Bowel Disease.
Gastroenterology, 2020 May 28,pii: S0016-5085(20)34735-1. doi: 10.1053/j.gastro.2020.05.063
Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review
D'Amico F, Wexner SD, Vaizey CJ, Gouynou C, Danese S, Peyrin-Biroulet L
United European Gastroenterol J, 2020 Jul 17;2050640620943699,doi: 10.1177/2050640620943699
Prevalence and duration of gastrointestinal symptoms before diagnosis of Inflammatory Bowel Disease and predictors of timely specialist review: a population-based study
Blackwell J, Saxena S, Jayasooriya N, Bottle A, Petersen I, Hotopf M, Alexakis C, Pollok RC, POP-IBD study group.
J Crohns Colitis, 2020 Jul 15,pii: jjaa146. doi: 10.1093/ecco-jcc/jjaa146
Food-induced Immediate Response of the Esophagus - a newly identified Syndrome in Patients with Eosinophilic Esophagitis
Biedermann L, Holbreich M, Atkins D, Chehade M, Dellon ES, Furuta GT, Hirano I, Gonsalves N, Greuter T, Katzka DA, De Rooij W, Safroneeva E, Schoepfer A, Schreiner P, Simon D, Uwe Simon H, Warners M, Bredenoord AJ, Straumann A
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab
Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN
Clin Gastroenterol Hepatol, 2020 Jul 12,pii: S1542-3565(20)30973-3. doi: 10.1016/j.cgh.2020.07.012
Gut microbiota-driven drug metabolism in inflammatory bowel disease
Crouwel F, Buiter HJC, de Boer NK
J Crohns Colitis, 2020 Jul 11,pii: jjaa143. doi: 10.1093/ecco-jcc/jjaa143
Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD
Hu S, Vich Vila A, Gacesa R, Collij V, Stevens C, Fu JM, Wong I, Talkowski ME, Rivas MA, Imhann F, Bolte L, van Dullemen H, Dijkstra G, Visschedijk MC, Festen EA, Xavier RJ, Fu J, Daly MJ, Wijmenga C, Zhernakova A, Kurilshikov A, Weersma RK
Gut, 2020 Jul 10,pii: gutjnl-2019-319706. doi: 10.1136/gutjnl-2019-319706
Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
Targownik LE, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA, Coward S, Jones J, Kaplan GG, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN
J Crohns Colitis, 2020 Jul 10,pii: jjaa050. doi: 10.1093/ecco-jcc/jjaa050
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
BMC Gastroenterol, 2020 Jul 8;20(1):211,doi: 10.1186/s12876-020-01332-w
Systematic Review: Histological Scoring of Strictures in Crohn's Disease
De Voogd FA, Mookhoek A, Gecse KB, De Hertogh G, Bemelman WA, Buskens CJ, D'Haens GR
J Crohns Colitis, 2020 Jul 9;14(6):734-742,doi: 10.1093/ecco-jcc/jjz177
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease
Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S
Inflamm Bowel Dis, 2020 Jul 7,pii: izaa078. doi: 10.1093/ibd/izaa078
Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases
Attauabi M, Zhao M, Bendtsen F, Burisch J
Inflamm Bowel Dis, 2020 Jul 6,pii: izaa167. doi: 10.1093/ibd/izaa167
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C, Bader G, Weisshof R, Jacobs M, Gutierrez A, Ciorba MA, Christophi GP, Patel A, Hirten RP, Colombel JF, Rubin DT, Ha C, Beniwal-Patel P, Ungaro RC, Syal G, Pekow J, Cohen BL, Yarur A
Clin Gastroenterol Hepatol, 2020 Jul 3,pii: S1542-3565(20)30913-7. doi: 10.1016/j.cgh.2020.06.050
No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis
Yzet C, Diouf M, Singh S, Brazier F, Turpin J, Nguyen-Khac E, Meynier J, Fumery M
Clin Gastroenterol Hepatol, 2020 Jul 3,pii: S1542-3565(20)30935-6. doi: 10.1016/j.cgh.2020.06.071
Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study
Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, Wang YP, Chen MH
Gut, 2020 Jun 23,pii: gutjnl-2020-320789. doi: 10.1136/gutjnl-2020-320789
Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice
Armuzzi A, Bouhnik Y, Cummings F, Bettey M, Pieper B, Kang T.
Identification of environmental risk factors associated with the development of Inflammatory Bowel Disease
van der Sloot KWJ, Weersma RK, Alizadeh BZ, Dijkstra G
J Crohns Colitis, 2020 Jun 23,pii: jjaa114. doi: 10.1093/ecco-jcc/jjaa114
The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis
Grant RK, Jones GR, Plevris N, Lynch RW, Jenkinson PW, Lees CW, Manship TA, Jagger FAM, Brindle WM, Shivakumar M, Satsangi J, Arnott IDR
Inflamm Bowel Dis, 2020 Jun 23,pii: izaa088. doi: 10.1093/ibd/izaa088
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: a Systematic Review and Pooled Meta-analysis
Faleck DM, Shmidt E, Huang R, Katta LG, Narula N, Pinotti R, Suarez-Farinas M, Colombel JF
Clin Gastroenterol Hepatol, 2020 Jun 19,pii: S1542-3565(20)30847-8. doi: 10.1016/j.cgh.2020.06.036
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: a Systematic Review and Pooled Meta-analysis
Faleck DM, Shmidt E, Huang R, Katta LG, Narula N, Pinotti R, Suarez-Farinas M, Colombel JF
Clin Gastroenterol Hepatol, 2020 Jun 19,pii: S1542-3565(20)30847-8. doi: 10.1016/j.cgh.2020.06.036
Fecal biomarkers in inflammatory bowel diseases: calprotectin versus lipocalin-2 - a comparative study
Zollner A, Schmiderer A, Reider SJ, Oberhuber G, Pfister A, Texler B, Watschinger C, Koch R, Effenberger M, Raine T, Tilg H, Moschen AR
J Crohns Colitis, 2020 Jun 18,pii: jjaa124. doi: 10.1093/ecco-jcc/jjaa124
The risk of rheumatoid arthritis among patients with inflammatory bowel disease: a systematic review and meta-analysis
Chen Y, Chen L, Xing C, Deng G, Zeng F, Xie T, Gu L, Yang H
BMC Gastroenterol, 2020 Jun 17;20(1):192,doi: 10.1186/s12876-020-01339-3
Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study
Clooney AG, Eckenberger J, Laserna-Mendieta E, Sexton KA, Bernstein MT, Vagianos K, Sargent M, Ryan FJ, Moran C, Sheehan D, Sleator RD, Targownik LE, Bernstein CN, Shanahan F, Claesson MJ
Gut, 2020 Jun 14,pii: gutjnl-2020-321106. doi: 10.1136/gutjnl-2020-321106
A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy
Coelho-Prabhu N, Bruining DH, Faubion WA, Kane SV, Kisiel JB, Papadakis KA, Pardi DS, Raffals LE, Schroeder KW, Tremaine WJ, Fruth K, Harmsen WS, Loftus EV
Inflamm Bowel Dis, 2020 Jun 12,pii: izaa146. doi: 10.1093/ibd/izaa146
Multicenter survey on mesalamine intolerance in patients with ulcerative colitis
Hiraoka S, Fujiwara A, Toyokawa T, Higashi R, Moritou Y, Takagi S, Matsueda K, Suzuki S, Miyaike J, Inokuchi T, Takahara M, Kato J, Okada H
Evaluation of Crohn's Disease Activity: Development of an Ultrasound Score in a Multicenter Study
Ripollés T, Poza J, Suarez Ferrer C, Martínez-Pérez MJ, Martín-Algíbez A, de Las Heras Paez B
Inflamm Bowel Dis, 2020 Jun 8,pii: izaa134. doi: 10.1093/ibd/izaa134
Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients
Frontali A, Cohen L, Bridoux V, Myrelid P, Sica G, Poggioli G, Espin E, Beyer-Berjot L, Laharie D, Spinelli A, Zerbib P, Sampietro G, Frasson M, Louis E, Danese S, Fumery M, Denost Q, Altwegg R, Nancey S, Michelassi F, Treton X, Panis Y
J Crohns Colitis, 2020 Jun 4,pii: jjaa107. doi: 10.1093/ecco-jcc/jjaa107
The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Leung KK, Tandon P, Govardhanam V, Maxwell C, Huang V
Inflamm Bowel Dis, 2020 May 29,pii: izaa122. doi: 10.1093/ibd/izaa122
HIGH-DOSE VITAMIN D DOES NOT PREVENT POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL
de Bruyn JR, Bossuyt P, Ferrante M, West RL, Dijkstra G, Witteman BJ, Wildenberg M, Hoentjen F, Franchimont D, Clasquin E, van der Bilt JD, Tollens T, Bemelman WA, D'Hoore A, Duijvestein M, D'Haens GR, Dutch-Belgian DETECT study group.
Clin Gastroenterol Hepatol, 2020 May 24,pii: S1542-3565(20)30698-4. doi: 10.1016/j.cgh.2020.05.037
Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar
Pagnini C, Di Paolo MC, De Angelis G, Torcolacci F, Milano M, Trinca D, Porciello R, Graziani MG
Inflamm Bowel Dis, 2020 May 27,pii: izaa128. doi: 10.1093/ibd/izaa128
Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications
Khan N, Patel D, Trivedi C, Kavani H, Medvedeva E, Pernes T, Xie D, Lewis J, Yang YX
Am J Gastroenterol, 2020 May 22,doi: 10.14309/ajg.0000000000000679
Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease
Lyles JL, Mulgund AA, Bauman LE, Su W, Fei L, Chona DL, Sharma P, Etter RK, Hellmann J, Denson LA, Minar P, Dykes DM, Rosen MJ
Inflamm Bowel Dis, 2020 May 25,pii: izaa102. doi: 10.1093/ibd/izaa102
Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn's Disease
Olaisen M, Flatberg A, Granlund AVB, Røyset ES, Martinsen TC, Sandvik AK, Fossmark R
Inflamm Bowel Dis, 2020 May 25,pii: izaa107. doi: 10.1093/ibd/izaa107
Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice
Pauwels RWM, de Vries AC, van der Woude CJ
A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy
Yao J, Jiang X, You JHS
Inflamm Bowel Dis, 2020 Apr 20,pii: izaa073. doi: 10.1093/ibd/izaa073
Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series
Phillips FM, Verstockt B, Sebastian S, Ribaldone DG, Vavricka S, Katsanos K, Slattery E, de Suray N, Flores C, Fries W, Vincenzi F, Capoferro E, Bachmann O, Kopylov U, ECCO CONFER investigators
J Crohns Colitis, 2020 Apr 22,pii: jjaa078. doi: 10.1093/ecco-jcc/jjaa078
Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience
Honap S, Chee D, Chapman TP, Patel M, Kent AJ, Ray S, Sharma E, Kennedy J, Cripps S, Walsh A, Goodhand JR, Ahmad T, Satsangi J, Irving PM, Kennedy NA, LEO (London, Exeter, Oxford) IBD Research Consortium.
J Crohns Colitis, 2020 Apr 13,pii: jjaa075. doi: 10.1093/ecco-jcc/jjaa075
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease
Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF
Gastroenterology, 2020 Mar 25,pii: S0016-5085(20)30390-5. doi: 10.1053/j.gastro.2020.03.039
Short- and long-term outcomes following side-to-side strictureplasty and its modification over the ileocecal valve for extensive Crohn's ileitis
Bislenghi G, Ferrante M, Sabino J, Verstockt B, Martin-Perez B, Fieuws S, Wolthuis A, Vermeire S, D'Hoore A
J Crohns Colitis, 2020 Mar 30,pii: jjaa066. doi: 10.1093/ecco-jcc/jjaa066
Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease (Kopie)
Ungar B, Ben-Shatach Z, Selinger L, Malik A, Albshesh A, Ben-Horin S, Eliakim R, Kopylov U, Carter D
United European Gastroenterol J, 2020 Mar;8(2):167-174,doi: 10.1177/2050640619878974
Evolving therapeutic goals in Crohn's disease management (Kopie)
Chateau T, Peyrin-Biroulet L
United European Gastroenterol J, 2020 Mar;8(2):133-139,doi: 10.1177/2050640619887316
Systematic review of development and content validity of patient-reported outcome measures in Inflammatory Bowel Disease: do we measure what we measure? (Kopie)
van Andel EM, Koopmann BDM, Crouwel F, Noomen CG, de Boer NKH, van Asseldonk DP, Mokkink LB
J Crohns Colitis, 2020 Mar 25,pii: jjaa057. doi: 10.1093/ecco-jcc/jjaa057
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis
Dellon ES, Collins MH, Rothenberg ME, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer A, Straumann A, Safroneeva E, Rodriguez C, Minton N, Hua SY, Hirano I
Clin Gastroenterol Hepatol, 2020 Mar 20,pii: S1542-3565(20)30348-7. doi: 10.1016/j.cgh.2020.03.036
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature
Papa V, Giustiniani MC, Lopetuso LR, Papa A
BMC Gastroenterol, 2020 Mar 24;20(1):76,doi: 10.1186/s12876-020-01221-2
Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: a nationwide study from the ENEIDA registry
Calafat M, Mañosa M, Mesonero F, Guardiola J, Mínguez M, Nos P, Vera I, Taxonera C, Iglesias E, Ricart E, Gisbert JP, Calvet X, García-López S, Monfort D, Pérez Calle JL, Riestra S, Gomollón F, Garcia-Planella E, Bermejo F, Vicent H, Martín-Arranz MD, Gutiérrez A, Torres P, Cañete F, Domènech E
J Crohns Colitis, 2020 Mar 23,pii: jjaa055. doi: 10.1093/ecco-jcc/jjaa055
Association Between Change in Inflammatory Aspects of Diet and Change in IBD-related Inflammation and Symptoms Over 1 Year: The Manitoba Living With IBD Study
Vagianos K, Shafer LA, Witges K, Targownik LE, Haviva C, Graff LA, Sexton KA, Lix LM, Sargent M, Bernstein CN
Inflamm Bowel Dis, 2020 Mar 24,pii: izaa052. doi: 10.1093/ibd/izaa052
Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection
Landemaine A, Petitcollin A, Brochard C, Miard C, Dewitte M, Le Balc'h E, Grainville T, Bellissant E, Siproudhis L, Bouguen G
Clin Gastroenterol Hepatol, 2020 Mar 18,pii: S1542-3565(20)30328-1. doi: 10.1016/j.cgh.2020.03.018
Management of rectal stump during laparoscopic subtotal colectomy for IBD. A comparative cohort study from 6 referral centres
Mege D, Stellingwerf M, Germain A, Colombo F, Pellino G, Di Candido F, Maggiori L, Foschi D, Buskens CJ, Adegbola S, Spinelli A, Warusavitarne J, Bemelman W, Sampietro G, D'Hoore A, Panis Y
J Crohns Colitis, 2020 Mar 11,pii: jjaa046. doi: 10.1093/ecco-jcc/jjaa046
The historical role and contemporary use of corticosteroids in inflammatory bowel disease
Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T
J Crohns Colitis, 2020 Mar 14,pii: jjaa053. doi: 10.1093/ecco-jcc/jjaa053
Small molecule oral targeted therapies in ulcerative colitis
Shivaji UN, Nardone OM, Cannatelli R, Smith SC, Ghosh S, Iacucci M
Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients with Inflammatory Bowel Disease Showing Lost Response to Infliximab
Yokoyama Y, Sawada K, Aoyama N, Yoshimura N, Sako M, Hirai F, Kashiwagi N, Suzuki Y
J Crohns Colitis, 2020 Mar 13,pii: jjaa051. doi: 10.1093/ecco-jcc/jjaa051
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 y Before Diagnosis
Torres J, Petralia F, Sato T, Wang P, Telesco SE, Choung RS, Strauss R, Li XJ, Laird RM, Gutierrez RL, Porter CK, Plevy S, Princen F, Murray JA, Riddle MS, Colombel JF
Gastroenterology, 2020 Mar 9,pii: S0016-5085(20)30327-9. doi: 10.1053/j.gastro.2020.03.007
Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission
Hanžel J, Zdovc J, Kurent T, Sever N, Javornik K, Tuta K, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Grabnar I, Drobne D
Clin Gastroenterol Hepatol, 2020 Feb 25,pii: S1542-3565(20)30203-2. doi: 10.1016/j.cgh.2020.02.033
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study
Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, Travis S, Danese S, Sandborn WJ, Schreiber S, Berg S, Zhou Q, Kligys K, Neimark E, Suleiman AA, D'Haens G, Colombel JF
Inflamm Bowel Dis, 2020 Feb 27,pii: izaa025. doi: 10.1093/ibd/izaa025
Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases
Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F
J Crohns Colitis, 2020 Feb 26,pii: jjaa035. doi: 10.1093/ecco-jcc/jjaa035
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
Sandborn WJ, Ghosh S, Panes J, Schreiber S, D'Haens G, Tanida S, Siffledeen J, Enejosa J, Zhou W, Othman AA, Huang B, Higgins PDR
Gastroenterology, 2020 Feb 21,pii: S0016-5085(20)30241-9. doi: 10.1053/j.gastro.2020.02.030
A systematic review and meta analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe
Roberts SE, Thorne K, Thapar N, Broekaert I, Benninga MA, Dolinsek J, Mas E, Miele E, Orel R, Pienar C, Ribes-Koninckx C, Thomson M, Tzivinikos C, Morrison-Rees S, John A, Williams JG
J Crohns Colitis, 2020 Feb 28,pii: jjaa037. doi: 10.1093/ecco-jcc/jjaa037
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis
Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F
United European Gastroenterol J, 2020 Feb;8(1):91-98,doi: 10.1177/2050640619895361
The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe
Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Salese L, daCosta DiBonaventura M
BMC Gastroenterol, 2020 Jan 21;20(1):18,doi: 10.1186/s12876-020-1164-0
Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: Short-term experience from a single tertiary clinical center
Lukas M, Malickova K, Kolar M, Bortlik M, Vasatko M, Machkova N, Hruba V, Duricova D, Lukas M
Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group
Shen B, Kochhar G, Navaneethan U, Farraye FA, Schwartz DA, Iacucci M, Bernstein CN, Dryden G, Cross R, Bruining DH, Kobayashi T, Lukas M, Shergill A, Bortlik M, Lan N, Lukas M, Tang SJ, Kotze PG, Kiran RP, Dulai PS, El-Hachem S, Coelho-Prabhu N, Thakkar S, Mao R, Chen G, Zhang S, Suárez BG, Lama YG, Silverberg MS, Sandborn WJ
Lancet Gastroenterol Hepatol, 2020 Jan 16,pii: S2468-1253(19)30366-8
First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ
Clin Gastroenterol Hepatol, 2020 Jan 13,pii: S1542-3565(20)30044-6.
Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group
Shen B, Kochhar GS, Navaneethan U, Cross RK, Farraye FA, Iacucci M, Schwartz DA, Gonzalez-Lama Y, Schairer J, Kiran RP, Kotze PG, Kobayashi T, Bortlik M, Liu X, Levy AN, González Suárez B, Tang SJ, Coelho-Prabhu N, Lukas M, Bruining DH, El-Hachem S, Charles RJ, Chen Y, Sood A, Mao R, Loras C, Dulai PS, Picoraro JA, Chiorean M, Lukas M, Shergill A, Silverberg MS, Sandborn WJ, Bernstein CN
Lancet Gastroenterol Hepatol, 2021 Jun 6,doi: 10.1016/S2468-1253(20)30394-0
Clinicopathological and prognostic evaluations of anorectal cancer after fecal diversion for patients with Crohn's disease
Kuroki H, Sugita A, Koganei K, Tatsumi K, Futatsuki R, Nakao E, Obara N, Arai K
BMC Gastroenterol, 2021 Apr 13;21(1):168,doi: 10.1186/s12876-021-01751-3
Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease
Alric H, Amiot A, Kirchgesner J, Tréton X, Allez M, Bouhnik Y, Beaugerie L, Carbonnel F, Meyer A
Natural History and Risk Stratification of Recurrent Crohn's Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study
Joustra V, Duijvestein M, Mookhoek A, Bemelman W, Buskens C, Koželj M, Novak G, Hindryckx P, Mostafavi N, D'Haens G
Perianal fistula-associated carcinoma in Crohn´s disease: a multicenter retrospective case control study
Palmieri C, Müller G, Kroesen AJ, Galata C, Rink AD, Morgenstern J, Kruis W
Ultrasonography tight control and monitoring in Crohn's disease during different biological therapies: a multicenter study
Calabrese E, Rispo A, Zorzi F, De Cristofaro E, Testa A, Costantino G, Viola A, Bezzio C, Ricci C, Prencipe S, Racchini C, Stefanelli G, Allocca M, Scotto di Santolo S, D'Auria MV, Balestrieri P, Ricchiuti A, Cappello M, Cavallaro F, Guarino AD, Maconi G, Spagnoli A, Monteleone G, Castiglione F
Clin Gastroenterol Hepatol, 2021 Mar 25,doi: 10.1016/j.cgh.2021.03.030
Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study
Dalal RS, Esckilsen S, Barnes EL, Pruce JC, Marcus J, Allegretti JR
Clin Gastroenterol Hepatol, 2021 Mar 25,doi: 10.1016/j.cgh.2021.03.028
Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients
Reinhold I, Blümel S, Schreiner J, Boyman O, Bögeholz J, Cheetham M, Rogler G, Biedermann L, Scharl M
Inflamm Intest Dis, 2021 Feb;6(1):38-47,doi: 10.1159/000511296